This is an important large retrospective single-institution study …[conducted in the context of a] tremendous increase in use of MRI for invasive and noninvasive breast cancer,” said Steven J. O’Day, MD, who moderated a presscast held just prior to the 2013 Breast Cancer Symposium.

“The study grounds us and shows us that we should be sure we are actually making a difference with the use of new technology. The authors are not saying that MRI can’t be used perioperatively or postoperatively, but they question its routine use in DCIS, because it is not an independent predictor of improving locoregional recurrence (LRR) or contralateral breast cancer (CBC) outcomes,” he added. Dr. O’Day is Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute in Los Angeles.

Dr. O’Day called for additional prospective studies to establish the optimal role of MRI in ductal carcinoma in situ and invasive breast cancer. ■

Disclosure: Dr. O’Day reported no potential conflicts of interest.